Clinical and endocrinological studies with the isomeric components of clomiphene citrate.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to T Klein.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Biodegradable implantable matrices containing bovine serum albumin were prepared from oligoesters by melting, and subsequently tested on in vitro albumin release. The linear poly (DL-lactic acid) and the branched terpolymer of DL-lactic acid, glycolic acid, and mannitol were synthesized. Products were of similar molecular weight and possessed different thermal and swelling characteristics. Oligoesters were loaded with 4% albumin and plasticized by 30% triacetin. Other additives added into the matrices as albumin stabilizers were divalent stearates and magnesium oxide. The influences of oligomer molecules constitution, divalent ion stearates or magnesium oxide addition, and triacetin concentration on the albumin release were quantified. SDS-PAGE revealed protein hydrolysis during the dissolution tests.
One-way mixed mother-child lymphocyte cultures (MMCLC) 4 to 20 years after the last delivery were studied with maternal responding and children's or fathers' stimulating cells (MMFLC) in 14 multiple child families with 18 sons and 20 daughters. HLA antigen typing locus A, B, DR was performed for all family members. As reported previously for newborn cells, a significantly increased maternal response could be observed in MMCLC with male as compared to female children's stimulating cells. Although the number of cases studied was small, it seems that the increased stimulating effect of male children's cells could also be observed when MMCLC values from children of different sex, and identical A,B,DR haplotypes were compared. In contrast to this, A,B,DR haploidentical children of the same sex seem to have a similar stimulating effect on the maternal response in MMCLC. The results suggest that male children's Y-chromosome-correlated minor histocompatibility antigens may additionally stimulate the maternal immune response in MMCLC.
The objective of this study was to compare the argyrophil nucleolar organizer region (Ag-NOR) counts of conjunctival nevi and melanomata and to compare the efficacy of this method in their differential diagnosis. Nine histologically diagnosed conjunctival nevi and three conjunctival malignant melanomas were studied. Representative sections were stained using the AgNOR technique. Fifty cells of each melanocytic lesion were randomly selected without knowing their histologic diagnosis. The AgNORs were visualized at a magnification of x1000. They consisted of clusters >1 micron in diameter and of satellites <1 micron in diameter, which were counted and recorded for each cell separately. The mean AgNOR count for the nevi was 1.12 clusters and 1.72 satellites per cell, while the count for the melanomas was 1.6 clusters and 6.8 satellites per cell. These results are statistically significant. There was no overlap between the number of AgNOR clusters and satellites in conjunctival nevi and melanomas, indicating that the AgNOR count might be a useful tool in distinguishing benign from malignant conjunctival melanocytic lesions.
Survival at 6, 12 and 24 months was studied in relation to the immunological findings before treatment and its variations after treatment in 600 patient and its variations after treatment in 600 patients with solid malignant tumours. Any change in any of these tests is a sign of poor prognosis proportional to the degree of this change. The most precise prognosis is given by an association of these tests. These two year survival rate for tumours without apparent spread was 87% if the tests were normal, 43% if one group of tests was disturbed and 11% if two groups of tests were abnormal. With local or regional spread, the survival was 52% in cases with normal tests, 12% if one group was disturbed, and 4% if both groups of tests were abnormal. With multiple metastases, the survival rates were respectively 24%, 4% and 0%. Thus the prognosis is less unfavourable for a tumour with general spread and normal immunological tests (24%) than for a localised tumour with a disturbance of two groups of immunological tests (11%). These immunological tests carried out before any treatment are thus very valuable in prognosis, independant of the apparent extension of the tumour. This indications are important in deciding on treatment.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The objective of our work was to investigate the pharmacodynamics of 5-fluorouracil (5-FU) in 23 patients with head and neck cancer treated with carboplatin (360 mg/m2) followed by 5 day continuous infusion of 5-FU (lg/m2/day). The pharmacokinetic profile of 5-FU was characterized for 36 cycles and was compared with the patient's tolerance. Toxic cycles (> or = grade 1, WHO grading) were associated with higher values of area under the serum concentration-time curve (AUC) than those of non toxic cycles. In addition, AUC values of 37000 ng.h.ml-1 and 21000 ng.h.ml-1 for the entire cycle and the half-cycle respectively were found to be predictive of toxicity. These threshold values are identical to those determined in our previous study with the cisplatin-5-FU regimen. Hence, patients treated with carboplatin and infusional 5-FU might benefit from 5-FU blood level, monitoring using the same dose adjustment diagram.